| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 665.75 | 2.4% | 15.5% |
| Total Income | 697.16 | 4.0% | 13.6% |
| Expenditure | 598.62 | 0.8% | 14.7% |
| PBT | 91.10 | 31.2% | 33.3% |
| Net Profit | 55.16 | 47.3% | 10.7% |
| OPM | 18.21% | 3.71pp | 22.73pp |
| NPM | 7.91% | 6.49pp | 0.21pp |
| EPS | 1.07 | 47.5% | 7.0% |
Aster DM Healthcare Delivers Steady Q3 FY26 Performance; Revenues Up by 13% YoY to INR 1,186 Crs
30 Jan 2026 · 30 Jan, 8:23 pm
Summary
Aster DM Healthcare has announced its financial results for the quarter ended December 31, 2025. The company's revenues for Q3 FY26 grew by 13% YoY to INR 1,186 Crs. The combined performance of Aster and Quality Care India Ltd (QCIL) showed a revenue growth of 15% to INR 2,366 Crs. The operating EBITDA (ex-Kasaragod) grew by 17% YoY to INR 237 Crs, with operating EBITDA margins (ex-Kasaragod) standing at 20.2%.
Key Highlights
- 1
Revenue for Q3 FY26 grew 13% YoY to INR 1,186 Crs
- 2
Operating EBITDA (ex-Kasaragod) grew 17% YoY to INR 237 Crs in Q3 FY26
- 3
Operating EBITDA Margins (ex-Kasaragod) stood at 20.2% in Q3 FY26
- 4
Normalised PAT (ex-Kasaragod) grew 22% YoY to INR 98 Crs in Q3 FY26
- 5
Aster + QCIL (Combined Proforma) delivered strong performance with revenue growth of 15% to INR 2,366 Crs in Q3 FY26
- 6
Operating EBITDA of Aster + QCIL grew by 22% to INR 503 Cr in Q3 FY26
- 7
Post NCLT order, Shareholders’ meeting to be convened between Feb 27 and Mar 13, 2026
Management Comments
Dr. Azad Moopen
Founder and Chairman, Aster DM Healthcare
As we move closer to the completion of merger between Aster and Quality Care India Limited, the proforma performance of the combined platform remains encouraging... With continued focus on strengthening clinical talent, leadership depth, and execution excellence, we remain well positioned to deliver sustainable expansion and provide high-quality, accessible healthcare at scale.
Informational and educational content only. Not investment advice.